GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaleaf Holdings Inc (OTCPK:CURLF) » Definitions » EV-to-EBIT

Curaleaf Holdings (Curaleaf Holdings) EV-to-EBIT : -144.67 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Curaleaf Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curaleaf Holdings's Enterprise Value is $4,646 Mil. Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-32 Mil. Therefore, Curaleaf Holdings's EV-to-EBIT for today is -144.67.

The historical rank and industry rank for Curaleaf Holdings's EV-to-EBIT or its related term are showing as below:

CURLF' s EV-to-EBIT Range Over the Past 10 Years
Min: -1189.69   Med: -16.47   Max: 149.82
Current: -144.67

During the past 10 years, the highest EV-to-EBIT of Curaleaf Holdings was 149.82. The lowest was -1189.69. And the median was -16.47.

CURLF's EV-to-EBIT is ranked worse than
100% of 676 companies
in the Drug Manufacturers industry
Industry Median: 17.145 vs CURLF: -144.67

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Curaleaf Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was $4,825 Mil. Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-32 Mil. Curaleaf Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -0.67%.


Curaleaf Holdings EV-to-EBIT Historical Data

The historical data trend for Curaleaf Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaleaf Holdings EV-to-EBIT Chart

Curaleaf Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -145.97 84.18 46.46 1,684.65 -163.68

Curaleaf Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -199.41 -46.03 -36.91 -163.68 -151.95

Competitive Comparison of Curaleaf Holdings's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curaleaf Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curaleaf Holdings's EV-to-EBIT falls into.



Curaleaf Holdings EV-to-EBIT Calculation

Curaleaf Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4646.490/-32.118
=-144.67

Curaleaf Holdings's current Enterprise Value is $4,646 Mil.
Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curaleaf Holdings  (OTCPK:CURLF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Curaleaf Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-32.118/4824.6763
=-0.67 %

Curaleaf Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was $4,825 Mil.
Curaleaf Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curaleaf Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Curaleaf Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Curaleaf Holdings (Curaleaf Holdings) Business Description

Traded in Other Exchanges
Address
420 Lexington Avenue, Suite 2035, New York, NY, USA, 10170-0052
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 18 states. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.